Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N. G., Fleming, G. F., … Monk, B. J. (2018). QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens. In Journal of Clinical Oncology (Vol. 36, pp. 5514–5514). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5514

Moore, Kathleen N., Angeles Alvarez Secord, Melissa Ann Geller, David S. Miller, Noelle Gillette Cloven, Gini F. Fleming, Andrea Elisabeth Wahner Hendrickson, et al. “QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.” In Journal of Clinical Oncology, 36:5514–5514. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5514.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven NG, Fleming GF, et al. QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5514–5514.

Moore, Kathleen N., et al. “QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5514–5514. Crossref, doi:10.1200/jco.2018.36.15_suppl.5514.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven NG, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea MC, Berek JS, Chan JK, Li Y, Clark R, Matulonis UA, Monk BJ. QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5514–5514.